New: NCI-funded clinical trial search
Mednet Logo
CommunityRheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

What factors do you consider when deciding to treat IgA nephropathy with immunosuppression in a patient with cirrhosis, given the possibility that IgA nephropathy could be secondary to cirrhosis?

1
5 Answers

Mednet MemberInvited Expert
Nephrology · University Of California San Francisco Medical Center At Parnassus

Proteinuria is the most important factor here. If there is significant proteinuria (>1 g/d) and no other clear reason for it, I would treat the IgA nephropathy with immunosuppression. Secondary IgA due to cirrhosis is usually not associated with significant proteinuria.

In a postmenopausal woman who is an avid marathon runner with no prior history of fractures, how would you approach treatment if DEXA shows severe osteoporosis at the distal radius (T-score −4.1) but only osteopenia at the hip and lumbar spine?

3 Answers

Mednet Member
Rheumatology · Brigham and Women's Rheumatology Arthritis Center

I would also make sure there was no error. I had a patient who had similar results, and it was a machine error- the machine was not calibrated correctly.

Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?

1
1 Answers

Mednet MemberInvited Expert
Rheumatology · Mayo Clinic College of Medicine

Once Avacopan is available for clinical use in the treatment of patients with AAV, providers will need to carefully weigh risks and benefits of the medication while considering other factors including cost.The ADVOCATE trial used a novel glucocorticoid toxicity index that captures common GC-related ...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

For a patient with orbital sarcoidosis who has achieved sustained clinical remission on adalimumab in combination with mycophenolate mofetil, how long would you recommend continuing mycophenolate before considering a gradual taper and discontinuation?

1
4 Answers

Mednet MemberInvited Expert
Rheumatology · Virginia Commonwealth University

Unfortunately, there is no sarcoidosis-specific evidence or guideline that sets how long to continue mycophenolate once orbital disease is in remission. Most of this data is extrapolated from other studies that indirectly measure disease flares. Alipour et al., PMID 40316030, published a study in Re...

How would you counsel a patient who is interested in using supplements (such as fish oil or turmeric) as an adjunct to treatment of inflammatory arthritis?

3 Answers

Mednet MemberInvited Expert
Rheumatology · Emory University

Drs. @Dr. First Last and @Dr. First Last expertly raise the key difficulty rheumatologists face with herbal medications: imparting a healthy respect for the potential risk:benefit (and limited data) about these agents against allowing patients to erroneously characterize their physician as close-min...

Is anifrolumab safe to use in patients with a history of malignancy?

1 Answers

Mednet MemberInvited Expert
Rheumatology · University of Alabama at Birmingham

Anifrolumab is not formally contraindicated in patients with a history of malignancy, but I would use it with individualized risk assessment.The United States Food and Drug Administration (FDA) label states that the effect of anifrolumab on malignancy development is unknown and recommends weighing t...

How do you select bisphosphonate versus denosumab when initiating treatment prompted by opportunistic CT findings of low L1 attenuation and a prevalent vertebral fracture?

1
1 Answers

Mednet MemberInvited Expert
Rheumatology · University of Kansas

Actually, I prefer calcitonin. It has few side effects and does not carry the risk of jaw necrosis.

Would you expect to see severe arthralgias within the first few days of immune-therapy in a patient without history of autoimmune disease?

1
2 Answers

Mednet Member
Rheumatology · Baptist Health Jacksonville Rheumatology

Yes, I agree with the excellent and comprehensive answer from Dr. @Dr. First Last- I’ve happened to see this strange presentation occur as well within a few days of starting immunotherapy.

Where in the sequence of biologics would you consider guselkumab for patients with active psoriatic arthritis despite standard DMARD therapy?

3 Answers

Mednet Member
Rheumatology · Mayo Clinic Jacksonville

This is an extremely important question and one that is likely to change as new data becomes available. It is important to remember that psoriatic arthritis (PsA) is a complex and heterogeneous disease and a single approach does not work for every patient. Based on the ACR/NPF 2019 PsA treatment gui...

How often do you draw screening ANAs for discoid lupus?

3 Answers

Mednet MemberInvited Expert
Rheumatology · Harvard Medical School

Because a positive ANA is associated with an increased risk of progression to SLE in patients with discoid lupus, I routinely check an ANA at the initial visit in virtually all patients. If negative, I repeat it only if new symptoms concerning systemic involvement arise (e.g., joint pain, cytopenias...